Quick Answer
Protalix BioTherapeutics, Inc. reported Total Revenue of $52.74 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $52.74M | -1.2% |
| 2024 | $53.40M | -18.5% |
| 2023 | $65.49M | +37.5% |
| 2022 | $47.64M | +24.2% |
| 2021 | $38.35M | -39.0% |
| 2020 | $62.90M | +15.0% |
| 2019 | $54.69M | +59.7% |
| 2018 | $34.24M | +62.4% |
| 2017 | $21.08M | +129.1% |
| 2016 | $9.20M | +110.8% |
| 2015 | $4.36M | +23.9% |
| 2014 | $3.52M | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $34.87M | +315.8% |
| 2011 | $8.39M | +26.3% |
| 2010 | $6.64M | +1611.9% |
| 2009 | $388.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.85M | -0.6% | +14.0% |
| June 30, 2025 | $15.66M | +16.2% | +54.8% |
| March 31, 2025 | $10.11M | +169.8% | -43.7% |
| September 30, 2024 | $17.96M | +73.6% | +33.3% |
| June 30, 2024 | $13.47M | -61.6% | +259.5% |
| March 31, 2024 | $3.75M | -60.9% | -63.8% |
| September 30, 2023 | $10.35M | -27.1% | -70.5% |
| June 30, 2023 | $35.08M | +300.7% | +265.8% |
- Protalix BioTherapeutics, Inc. showed a decrease of -1.2% in Total Revenue compared to the prior fiscal year.
- Over the 2009–2025 period, Protalix BioTherapeutics, Inc.’s total revenue has grown by 13493.8% (from $388.0 thousand to $52.74 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: